Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy
Open accessThe DOI matches its Crossref record; 24 of the 26 references it cites were found in a registry or an index; 6 of the 44 sources its claims cite were checked for support.
Abstract
As the first radiopharmaceutical for Peptide Receptor Radionuclide Therapy (PRRT), Lutathera® was approved by the EMA in 2017 and the FDA in 2018 for the treatment of somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors.
Overview
CoChat Summary
## TL;DR
Lutathera® ([177Lu]Lu-DOTA-TATE) is presented as the first FDA- and EMA-approved radiopharmaceutical for peptide receptor radionuclide therapy (PRRT) for adults with SSTR-positive gastroenteropancreatic neuroendocrine tumors. The paper summarizes its mechanism, indication, dosing, manufacturing, and the clinical trial results that supported approval.
## Key findings
- Lutathera® was approved by the EMA in 2017 and the FDA in 2018; the paper also notes Canadian approval in 2019.
- Its active ingredient is [177Lu]Lu-DOTA-TATE, which combines lutetium-177 with the somatostatin analogue DOTA-TATE to target SSTR-expressing tumor cells and cause DNA single- and double-strand breaks.
- The recommended treatment schedule is four infusions of 7.4 GBq every 8 weeks; intervals may be extended to 16 weeks if dose-modifying toxicity occurs.
- In the NETTER-1 phase III trial (229 patients), progression-free survival favored [177Lu]Lu-DOTA-TATE plus octreotide LAR over high-dose octreotide LAR: 65% vs 11% of patients were progression-free at 20 months (p < 0.0001), median PFS was not reached vs 8.5 months, and objective response rate was 18% vs 3% (p < 0.001).
## Methods
- Narrative review/overview of Lutathera® covering chemical properties, clinical indication, application, pharmacology/pharmacokinetics, manufacturing, and regulatory status.
- Draws on published clinical studies and product monographs, including the Erasmus phase I/II study (1,214 patients) and the NETTER-1 phase III trial (229 patients).
- Summarizes reported trial endpoints and pharmacokinetic/dosimetry data from the cited studies rather than presenting new original analyses.
## Limitations
- The paper does not report any new original experimental or clinical data; it synthesizes prior literature and regulatory documents.
- The text makes evident that some sections are only brief summaries and refer readers to product monographs or cited studies for details; this limits methodological depth and reproducibility of the review’s own synthesis.
- Not stated in the paper.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
5 Valid · 0 Not valid · 33 Not checked · 1 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The positive results of the multicenter phase-III clinical trial [16], NETTER-1, comparing the treatment with [177Lu]Lu-DOTA-TATE to the treatment with high doses of octreotide LAR, paved the way for its approval by national and international medicines agencies in America and Europe.”
§ Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy > 4. Conclusions
What the sources say
- Partly supportedcites [16] Strosberg, 2017, NETTER-1 Trial Investigators. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors, N. Engl. J. Med. sourceExperimental — accuracy not yet measured
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Another therapeutic effect is the radiation-induced bystander effect: Cells that have not been directly exposed to ionizing radiation, but are in the neighborhood of such cells, behave as if they have been directly hit [31].”
§ Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy > 3. Medicinal and Pharmaceutical Overview > 3.3. Pharmacology and Pharmacokinetics In a study by Reubi et al. [29], the SSTR subtype affinity profile of a number of somatostatin analogues was investigated, showing, e.g., that DOTA-TATE exhibits high affinity for human SSTR2 (IC50 of 1.5 ± 0.4 nM) with much less binding affinity for all other human SSTRs. Complexing this peptide with yttrium resulted in a comparable binding affinity profile and complexing with gallium in an even higher affinity for SSTR2 (IC50 of 0.2 ± 0.04 nM). [177Lu]Lu-DOTA-TATE shows high binding affinity for SSTR2 as well, and therefore binds to malignant cells with an upregulation of SSTR2 [8]. Upon binding to the receptor, the radiolabeled peptide becomes internalized into the cell and the β particle emission of 177Lu induces DNA single- and double-strand breaks, in case of double-strand breaks leading to cell death of the tumor and its SSTR-positive lesions [8]. Figure 2 gives a simplified overview on the mechanism of action of [177Lu]Lu-DOTA-TATE. Due to the range of the β particles in comparison to the diameter of a cell, the emitted β particles traverse several cells (10–1000) [30]. This effect has been termed “cross-fire effect” and is responsible for the possible destruction of multiple cells in the vicinity of the tracer-accumulating cell [31]. Using β particle emitters, the cross-fire effect is critical for the improvement of tumor dose homogeneity and for ensuring a sufficient dose for each cell [32]. Another therapeutic effect is the radiation-induced bystander effect: Cells that have not been directly exposed to ionizing radiation, but are in the neighborhood of such cells, behave as if they have been directly hit [31]. Owing to the nanomolar concentration (10 µg/mL; 6.3 × 10−3 nM) of the peptide in the sterile injection solution [8], no clinically relevant pharmacodynamic effects are expected. The pharmacokinetic properties of Lutathera® are described in the product monographs [8,27]. [177Lu]Lu-DOTA-TATE is immediately and completely bioavailable through i. v. injection and clears rapidly from blood. The effective half-life in blood in a study with 31 patients was determined to be 0.31 ± 0.13 h [33]. The effective blood elimination half-life is 3.5 ± 1.4 h [26]. Studies using non-radioactive [175Lu]Lu-DOTA-TATE showed that protein binding to human plasma is ca. 50% and that transchelation of lutetium to serum proteins is not occurring. Four hours after administration, [177Lu]Lu-DOTA-TATE shows uptake in kidneys, tumoral lesions, liver, and spleen, and in some patients, additionally in the pituitary gland and thyroid. Kidney uptake can be decreased by co-administration of amino acids (see above), which reduces the re-absorption of the radiopharmaceutical through the proximal tubules [34]. This is mandatory because the compound is primarily eliminated through the renal system. Data from the Erasmus phase-I/-II and NETTER-1 phase-III trials indicate that ca. 60% of the radiopharmaceutical is eliminated in the urine within 24 h post injection (p. i.) and ca. 65% within 48 h p. i. Metabolism of [177Lu]Lu-DOTA-TATE is negligible, as shown by radio-HPLC analysis of urine samples collected 48 h p. i. Radiation dosimetry of [177Lu]Lu-DOTA-TATE has been evaluated in 20 patients in clinical studies [15,27]. The critical organ is the bone marrow. However, with the recommended cumulative dose of 29.6 GBq (4 × 7.4 GBq), neither correlation of hematological toxicity with total administered radioactivity nor with bone marrow absorbed dose has been observed. The kidney is not a critical organ when co-administration of appropriate amino acids is conducted. The median radiation dose to the kidneys can be reduced by 47% (34% to 59%) with co-administration of amino acids [26]. Table 1 summarizes estimated radiation absorbed doses for Lutathera® in the NETTER-1 trial for main organs [26,27].
What the sources say
- Supportedcites [31] Haberkorn, 2017, The Future of Radioligand Therapy: α, β, or Both?, J. Nucl. Med. source
The discussion of the radiation-induced bystander effect (p. 1) explicitly defines it as neighboring cells that were not directly exposed to ionizing radiation behaving as though they were exposed. The Figure 1 caption (p. 2) likewise describes effects on neighboring, unexposed cells. (LLM, conf=0.95)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
None of the sources cited for this claim could be matched to a paper, so there is nothing to check it against.
In the paper
“The clinical indication of Lutathera® is the treatment of unresectable or metastatic, progressive, well-differentiated (G1 and G2 grade) SSTR-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adults [15,27].”
§ Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy > 3. Medicinal and Pharmaceutical Overview > 3.1. Clinical Indication
What the sources say
- Not matchedcites [15] (2019, April 23). Lutathera® Summary of Product Characteristics. Available online: https://www.ema.europa.eu/en/documents/product-information/lutathera-epar-product-information_en.pdf.
We searched by its title and found no matching paper.
- Not matchedcites [27] (2019, April 23). Product Monograph for LUTATHERATM for Canada. Available online: https://pdf.hres.ca/dpd_pm/00049099.pdf.
We searched by its title and found no matching paper.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
In the paper
“It could also be demonstrated that treatment with [177Lu]Lu-DOTA-TATE was safe and well tolerated [8].”
§ Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy > 1. Introduction
What the sources say
- Not matchedcites [8] (2019, April 18). Product Monograph LUTATHERA®. Available online: https://www.samnordic.se/wp-content/uploads/2018/05/LUTATHERA-MONOGRAPH-120218.pdf.
We searched by its title and found no matching paper.
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
In the paper
“Using the concept of PRRT, Lutathera® combines the radionuclide 177Lu with the somatostatin analogue DOTA-TATE, thus delivering ionizing radiation specifically to tumor cells expressing somatostatin receptors.”
- Also stated in: § 4. Conclusions · plain
“Combining the radionuclide 177Lu with the somatostatin analogue DOTA-TATE, [177Lu]Lu-DOTA-TATE delivers ionizing radiation specifically and selectively to tumor cells expressing SSTRs.”
§ Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy > Abstract
What the sources say
- Not matchedcites [8] (2019, April 18). Product Monograph LUTATHERA®. Available online: https://www.samnordic.se/wp-content/uploads/2018/05/LUTATHERA-MONOGRAPH-120218.pdf.
We searched by its title and found no matching paper.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § 4. Conclusions · plain
12 more claims
Create a free account to see all 39 claims and to verify the 4 references still open.
- It may state two separate claims as one. 21
- Probably not a substantial claim. 3
Citations
Cites
Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth Hormone
Brazeau, P., Vale, W., Burgus, R., Ling, N., Butcher, M., Rivier, J., & Guillemin, R. (1973) · Science · doi:10.1126/science.179.4068.77 · Cited by 3,532 · cited 1×
“The development of these radiolabeled somatostatin ligands was a very long scientific journey that started with the first description of somatostatin more than 45 years ago [10].”
BackgroundPhase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors
Strosberg, J., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., Mittra, E., Kunz, P. L., Kulke, M. H., Jacene, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1607427 · Cited by 3,308
Reubi, J. C., Schär, J.-C., Waser, B., Wenger, S., Heppeler, A., Schmitt, J. S., & Mäcke, H. R. (2000) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590050034 · Cited by 1,127
LOCALISATION OF ENDOCRINE-RELATED TUMOURS WITH RADIOIODINATED ANALOGUE OF SOMATOSTATIN
Krenning, E. P., Breeman, W. A. P., Kooij, P. P. M., Lameris, J. S., Bakker, W. H., Koper, J. W., Ausema, L., Reubi, J. C., & Lamberts, S. W. J. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91258-0 · Cited by 625 · cited 1×
“The first radiolabeled SST analog used for imaging was [123I, Tyr3]octreotide in 1989 [12], while early therapeutic studies used [111In]In-DTPA-octreotide in the mid to late 1990s, since other chelated somatostatin ligands were not available [11].”
MethodSomatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors
Kwekkeboom, D. J., Kam, B. L., van Essen, M., Teunissen, J. J. M., van Eijck, C. H. J., Valkema, R., de Jong, M., de Herder, W. W., & Krenning, E. P. (2010) · Endocrine-Related Cancer · doi:10.1677/erc-09-0078 · Cited by 466 · cited 1×
“The first radiolabeled SST analog used for imaging was [123I, Tyr3]octreotide in 1989 [12], while early therapeutic studies used [111In]In-DTPA-octreotide in the mid to late 1990s, since other chelated somatostatin ligands were not available [11].”
MethodAntibody-targeted radiation cancer therapy
Milenic, D. E., Brady, E. D., & Brechbiel, M. W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1413 · Cited by 380
Consensus nomenclature rules for radiopharmaceutical chemistry — Setting the record straight
Coenen, H. H., Gee, A. D., Adam, M., Antoni, G., Cutler, C. S., Fujibayashi, Y., Jeong, J. M., Mach, R. H., Mindt, T. L., Pike, V. W., et al. (2017) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2017.09.004 · Cited by 226 · cited 1×
“In January 2018 (26 January 2018), Lutathera® ([177Lu]Lu-DOTA-TATE (for rules on nomenclature, see [1,2])) was approved by the FDA [3] for the treatment of somatostatin receptor (SSTR) positive gastroenteropancreatic neuroendocrine tumors.”
BackgroundElschot, M., Vermolen, B. J., Lam, M. G. E. H., de Keizer, B., van den Bosch, M. A. A. J., & de Jong, H. W. A. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055742 · Cited by 209
Targeted α-therapy–past, present, future?
Brechbiel, M. W. (2007) · Dalton Transactions · doi:10.1039/b704726f · Cited by 151
Crystal structure and solution dynamics of the lutetium(III) chelate of DOTA
Aime, S., Barge, A., Botta, M., Fasano, M., Danilo Ayala, J., & Bombieri, G. (1996) · Inorganica Chimica Acta · doi:10.1016/0020-1693(96)05130-4 · Cited by 148
Research works printed but not linked: 3
- Erion, 1999, High radiotherapeutic efficacy of [Lu-177]-DOTA-Y3-octreotate in a rat tumor model [abstract], J. Nucl. Med., 40, 223
- Nagy, 2004, Radionuclide Therapy, Handbook of Nuclear Chemistry, Volume 4, 315
- Rolleman, 1996, Inhibition of Renal Uptake of Indium-111-DTPAOctreotide, J. Nucl. Med., 37, 1388
Cited by
Hennrich, U., & Eder, M. (2022) · Pharmaceuticals · doi:10.3390/ph15101292 · Cited by 318
Self-citationLammers, T. (2024) · Advanced Materials · doi:10.1002/adma.202312169 · Cited by 290
Antibody–drug conjugates: Recent advances in payloads
Wang, Z., Li, H., Gou, L., Li, W., & Wang, Y. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.06.015 · Cited by 264
Herrera-Barrera, M., Ryals, R. C., Gautam, M., Jozic, A., Landry, M., Korzun, T., Gupta, M., Acosta, C., Stoddard, J., Reynaga, R., et al. (2023) · Science Advances · doi:10.1126/sciadv.add4623 · Cited by 239
Ludwig, B. S., Kessler, H., Kossatz, S., & Reuning, U. (2021) · Cancers · doi:10.3390/cancers13071711 · Cited by 238
Fu, C., Yu, L., Miao, Y., Liu, X., Yu, Z., & Wei, M. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.07.020 · Cited by 209
[68Ga]Ga-DOTA-TOC: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging
Hennrich, U., & Benešová, M. (2020) · Pharmaceuticals · doi:10.3390/ph13030038 · Cited by 184
Self-citationPeptide–drug conjugate-based novel molecular drug delivery system in cancer
Zhu, Y., Tang, K., & Lv, J. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.07.001 · Cited by 162
Kang, M. S., Kong, T. W. S., Khoo, Y. X. J., & Loh, T. (2021) · Chemical Science · doi:10.1039/d1sc02973h · Cited by 163
Overview of Radiolabeled Somatostatin Analogs for Cancer Imaging and Therapy
Eychenne, R., Bouvry, C., Bourgeois, M., Loyer, P., Benoist, É., & Lepareur, N. (2020) · Molecules · doi:10.3390/molecules25174012 · Cited by 138
Research advances in peptide‒drug conjugates
Gong, L., Zhao, H., Liu, Y., Wu, H., Liu, C., Chang, S.-Y., Chen, L., Jin, M., Wang, Q., Gao, Z., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.02.013 · Cited by 122
Theranostic approaches in nuclear medicine: current status and future prospects
Filippi, L., Chiaravalloti, A., Schillaci, O., Cianni, R., & Bagni, O. (2020) · Expert Review of Medical Devices · doi:10.1080/17434440.2020.1741348 · Cited by 117
Targeted Brain Tumor Radiotherapy Using an Auger Emitter
Pirovano, G., Jannetti, S. A., Carter, L. M., Sadique, A., Kossatz, S., Guru, N., França, P. D. D. S., Maeda, M., Zeglis, B. M., Lewis, J. S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2440 · Cited by 106
“20 potential of Auger-emitting molecules for targeted radiotherapy, a fast-growing and promising field (41, 42).”
BackgroundRondon, A., & Degoul, F. (2019) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.9b00761 · Cited by 101
Recent Advances in Radiometals for Combined Imaging and Therapy in Cancer
Álvarez, N. H., Bauer, D., Hernández‐Gil, J., & Lewis, J. S. (2021) · ChemMedChem · doi:10.1002/cmdc.202100135 · Cited by 104
Optimized lipid nanoparticles (LNPs) for organ-selective nucleic acids delivery in vivo
Zhang, T., Yin, H., Li, Y., Yang, H., Ge, K., Zhang, J., Yuan, Q., Dai, X., Naeem, A., Weng, Y., et al. (2024) · iScience · doi:10.1016/j.isci.2024.109804 · Cited by 119
Clinical Advances and Perspectives in Targeted Radionuclide Therapy
Lepareur, N., Ramée, B., Mougin‐Degraef, M., & Bourgeois, M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15061733 · Cited by 100
Strosberg, J., Leeuwenkamp, O. R., & Siddiqui, M. K. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102141 · Cited by 94
A Dimeric FAP-Targeting Small-Molecule Radioconjugate with High and Prolonged Tumor Uptake
Galbiati, A., Zana, A., Bocci, M., Millul, J., Elsayed, A., Mock, J., Neri, D., & Cazzamalli, S. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.264036 · Cited by 89
Terbium radionuclides for theranostic applications in nuclear medicine: from atom to bedside
Laere, C. V., Koole, M. J. B., Deroose, C. M., et al. (2024) · Theranostics · doi:10.7150/thno.92775 · Cited by 78
Expanding Theranostic Radiopharmaceuticals for Tumor Diagnosis and Therapy
Barca, C., Griessinger, C. M., Faust, A., Depke, D. A., Essler, M., Windhorst, A. D., Devoogdt, N., Brindle, K. M., Schäfers, M. A., Zinnhardt, B., et al. (2021) · Pharmaceuticals · doi:10.3390/ph15010013 · Cited by 84
Shi, M., Jakobsson, V., Greifenstein, L., Khong, P.-L., Chen, X., Baum, R. P., & Zhang, J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1034315 · Cited by 68
Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors
Basu, S. K., Parghane, R. V., Kamaldeep, & Chakrabarty, S. (2020) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2020.05.004 · Cited by 72
Abdollahi, H., Yousefirizi, F., Shiri, I., Brosch-Lenz, J., Mollaheydar, E., Fele‐Paranj, A., Shi, K., Zaidi, H., Alberts, I., Soltani, M., et al. (2024) · Theranostics · doi:10.7150/thno.93973 · Cited by 78
“For example, Lu-177-Lutathera was approved with a standard administration dosage (7.4 GBq every 8 weeks for a total of 4 administrations) without any requirements for personalized dosimetry [13].”
MethodInfluentialDevelopment of radiopharmaceuticals for targeted alpha therapy: Where do we stand?
Pallares, R. M., & Abergel, R. J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1020188 · Cited by 75
Reducing the renal retention of low- to moderate-molecular-weight radiopharmaceuticals
Chigoho, D. M., Bridoux, J., & Hernot, S. (2021) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2021.06.008 · Cited by 69
Shabsigh, M., & Solomon, L. A. (2024) · Chemical & Biomedical Imaging · doi:10.1021/cbmi.4c00030 · Cited by 66
Strategies for the Nuclear Delivery of Metal Complexes to Cancer Cells
Huynh, M., Vinck, R., Gibert, B., & Gasser, G. (2024) · Advanced Materials · doi:10.1002/adma.202311437 · Cited by 64
He, X., Li, J., Liang, X., Mao, W., Deng, X., Qin, M., Su, H., & Wu, H. (2024) · Nature Communications · doi:10.1038/s41467-024-47188-6 · Cited by 70
Radioactive polymeric nanoparticles for biomedical application
Wu, S.-T., Helal‐Neto, E., Matos, A. P. D. S., Jafari, A. H., Kozempel, J., Silva, Y. J. D. A., Larrea, C. S., Alves, S., Ricci‐Júnior, E., Alexis, F., et al. (2020) · Drug Delivery · doi:10.1080/10717544.2020.1837296 · Cited by 59
“In 2017, FDA Approves Novel Radio-peptide Targeted Therapy Clinical Trial for Neuroendocrine Cancer (Hennrich and Kopka, 2019).”
BackgroundPeptide-Based Bioconjugates and Therapeutics for Targeted Anticancer Therapy
Yang, S.-B., Banik, N., Han, B., Lee, D.-N., & Park, J. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14071378 · Cited by 60
Urso, L., Nieri, A., Uccelli, L., Castello, A., Artioli, P., Cittanti, C., Marzola, M. C., Florimonte, L., Castellani, M., Bissoli, S., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041110 · Cited by 64
Peptide Binder to Glypican-3 as a Theranostic Agent for Hepatocellular Carcinoma
Lin, F., Clift, R., Ehara, T., Yanagida, H., Horton, S., Noncovich, A., Guest, M., Kim, D., Salvador, K., Richardson, S., et al. (2024) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.266766 · Cited by 67
Carrier systems of radiopharmaceuticals and the application in cancer therapy
Zhang, T., Lei, H., Chen, X., Dou, Z., Yu, B., Su, W., Wang, W., Jin, X., Katsube, T., Wang, B., et al. (2024) · Cell Death Discovery · doi:10.1038/s41420-023-01778-3 · Cited by 65
Li, M., Chen, S., Lai, Y., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.669509 · Cited by 50
FDA-Approved Small Molecule Compounds as Drugs for Solid Cancers from Early 2011 to the End of 2021
Sochacka-Ćwikła, A., Mą̨czyński, M., & Regiec, A. (2022) · Molecules · doi:10.3390/molecules27072259 · Cited by 59
Martian, P. C., Tertiş, M., Leonte, D., Hădade, N. D., Cristea, C., & Crisan, O. (2024) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2024.116488 · Cited by 62
de Roode, K. E., Joosten, L., & Béhé, M. P. (2024) · Pharmaceuticals · doi:10.3390/ph17020256 · Cited by 54
“Nowadays, co-infusion of amino acids (L-lysine and L-arginine) is a standardized regimen for kidney protection in TRT with [ 177 Lu]Lu-DOTA-TATE (Lutathera) [39].”
BackgroundMethodNanoparticles in Targeted Alpha Therapy
Majkowska‐Pilip, A., Gawęda, W., Żelechowska-Matysiak, K., Wawrowicz, K., & Bilewicz, A. (2020) · Nanomaterials · doi:10.3390/nano10071366 · Cited by 50
Laudicella, R., Comelli, A., Liberini, V., Vento, A., Stefano, A., Spataro, A., Crocè, L., Baldari, S., Bambaci, M., Deandreis, D., et al. (2022) · Cancers · doi:10.3390/cancers14040984 · Cited by 51
Peptide Receptor Radionuclide Therapy
Hofland, J., Brabander, T., Verburg, F. A., Feelders, R. A., & de Herder, W. W. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac574 · Cited by 59
Radiolabelling small and biomolecules for tracking and monitoring
Edelmann, M. R. (2022) · RSC Advances · doi:10.1039/d2ra06236d · Cited by 56
Bogdanović, B., Fagret, D., Ghezzi, C., & Montemagno, C. (2024) · Pharmaceuticals · doi:10.3390/ph17111556 · Cited by 55
Loveless, C. S., Blanco, J. R., Diehl, G., et al. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.242941 · Cited by 44
“7d) can be used in theranostics to diagnose and treat SSTR-expressing neuroendocrine tumors (2,3).”
BackgroundMethodPeptide Radioligands in Cancer Theranostics: Agonists and Antagonists
Nock, B. A., Kanellopoulos, P., Joosten, L., Mansi, R., & Μάινα, Θ. (2023) · Pharmaceuticals · doi:10.3390/ph16050674 · Cited by 53
Anti-SSTR2 antibody-drug conjugate for neuroendocrine tumor therapy
Si, Y., Kim, S., Ou, J., et al. (2020) · Cancer Gene Therapy · doi:10.1038/s41417-020-0196-5 · Cited by 44
Foster, A., Nigam, S., Tatum, D. S., Raphael, I., Xu, J., Kumar, R., Plakseychuk, E., Latoche, J. D., Vincze, S., Li, B., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103571 · Cited by 47
“For example, DOTA-octreotate (dotatate) radiolabelled with Lu-177 ((177)Lu-dotatate; Lutathera) or Ga-68 ((68)Ga-dotatate; NetSpot) are FDA-approved for TRT and PET imaging, respectively [5,6], emphasizing the translational potential of theranostic agents with a single chelator for both therapy and PET.”
BackgroundTheragnostic Aspects and Radioimmunotherapy in Pediatric Tumors
Cimini, A., Ricci, M., Chiaravalloti, A., Filippi, L., & Schillaci, O. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113849 · Cited by 47
“4 GBq administered in 4 cycles at an interval of 8 weeks [50].”
Miranda, V. M. (2021) · Reviews in Inorganic Chemistry · doi:10.1515/revic-2020-0030 · Cited by 48
Puglioli, S., Schmidt, E., Pellegrino, C. E., Prati, L., Oehler, S., Luca, R. D., Galbiati, A., Comacchio, C., Nadal, L., Scheuermann, J., et al. (2022) · Chem · doi:10.1016/j.chempr.2022.10.006 · Cited by 47
Peptides for trans‐blood–brain barrier delivery
Blades, R., Ittner, L. M., & Tietz, O. (2023) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.4023 · Cited by 46
Safety and Therapeutic Optimization of Lutetium-177 Based Radiopharmaceuticals
Ladrière, T., Faudemer, J., Levigoureux, E., Peyronnet, D., Desmonts, C., & Vigne, J. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041240 · Cited by 58
Radiolabeled Somatostatin Analogues for Diagnosis and Treatment of Neuroendocrine Tumors
Ambrosini, V., Zanoni, L., Filice, A., Lamberti, G., Argalia, G., Fortunati, E., Campana, D., Versari, A., & Fanti, S. (2022) · Cancers · doi:10.3390/cancers14041055 · Cited by 50
“Despite the efforts and the numerous publications to further improve PRRT by using dosimetry [154], a recent survey in European centers applying radionuclide therapies has shown that dosimetry is rarely or never used in more than half of centers; moreover, its results barely influence treatment [162].”
BackgroundInfluentialRecent Advances in Targeted Cancer Therapy: Are PDCs the Next Generation of ADCs?
Zhang, B., Wang, M., Sun, L., Liu, J., Yin, L., Xia, M., Zhang, L., Liu, X., & Cheng, Y. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00106 · Cited by 44
Potential Roles of Total-Body PET/Computed Tomography in Pediatric Imaging
Nardo, L., Schmall, J. P., Werner, T. J., Malogolowkin, M. H., Badawi, R. D., & Alavi, A. A. (2020) · PET Clinics · doi:10.1016/j.cpet.2020.03.009 · Cited by 40
Lu, X., Lu, C., Yang, Y., Shi, X., Wang, H., Yang, N., Yang, K., & Zhang, X. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.624534 · Cited by 42
The Landmark Series: Management of Small Bowel Neuroendocrine Tumors
Tran, C. G., Sherman, S. K., & Howe, J. R. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-020-09566-4 · Cited by 42
Galbiati, A., Bocci, M., Ravazza, D., Mock, J., Gilardoni, E., Neri, D., & Cazzamalli, S. (2024) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.268200 · Cited by 46
Developing scandium and yttrium coordination chemistry to advance theranostic radiopharmaceuticals
Carter, K. P., Deblonde, G. J. ‐., Lohrey, T. D., Bailey, T. A., An, D. D., Shield, K. M., Lukens, W. W., & Abergel, R. J. (2020) · Communications Chemistry · doi:10.1038/s42004-020-0307-0 · Cited by 39
Cassells, I., Ahenkorah, S., Burgoyne, A. R., de Voorde, M. V., Deroose, C. M., Cardinaels, T., Bormans, G. M., Ooms, M., & Cleeren, F. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.675122 · Cited by 39
Kind, F., Michalski, K., Yousefzadeh‐Nowshahr, E., Meyer, P. T., Mix, M. D., & Ruf, J. (2022) · EJNMMI Research · doi:10.1186/s13550-022-00891-1 · Cited by 38
Evolution of Neuroendocrine Tumor Therapy
O’Dorisio, T. M., Harris, A. G., & O'Dorisio, M. S. (2020) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2019.11.002 · Cited by 48
“Clickable” Albumin Binders for Modulating the Tumor Uptake of Targeted Radiopharmaceuticals
Brandt, F., Ullrich, M., Laube, M., Kopka, K., Bachmann, M. P., Löser, R., Pietzsch, J., Pietzsch, H., van den Hoff, J., & Wodtke, R. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01791 · Cited by 38
Self-citationЛаренков, А. А., Mitrofanov, Y. A., Pavlenko, E., & Rakhimov, M. G. (2023) · Molecules · doi:10.3390/molecules28041884 · Cited by 37
Peptide‐Drug Conjugates: A New Hope for Cancer
Armstrong, A. J., Coburn, F., Nsereko, Y., & Musaimi, O. A. (2025) · Journal of Peptide Science · doi:10.1002/psc.70040 · Cited by 44
Peptide-Based Combination Nanoformulations for Cancer Therapy
Mehrotra, N., Kharbanda, S. M., & Singh, H. (2020) · Nanomedicine · doi:10.2217/nnm-2020-0220 · Cited by 37
Commercial and business aspects of alpha radioligand therapeutics
Ostuni, E., & Taylor, M. R. G. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2022.1070497 · Cited by 38
Peptide Therapeutics: Unveiling the Potential against Cancer—A Journey through 1989
Musaimi, O. A. (2024) · Cancers · doi:10.3390/cancers16051032 · Cited by 40
Exploring the Chemical Features and Biomedical Relevance of Cell-Penetrating Peptides
Moreno‐Vargas, L. M., & Prada‐Gracia, D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms26010059 · Cited by 52
Radiolabeled Nanocarriers as Theranostics—Advancement from Peptides to Nanocarriers
Desai, P. B., Rimal, R., Sahnoun, S. E. M., Mottaghy, F. M., Möller, M., Morgenroth, A., & Singh, S. (2022) · Small · doi:10.1002/smll.202200673 · Cited by 35
Combination radionuclide therapy: A new paradigm
Suman, S. K., Subramanian, S., & Mukherjee, A. (2021) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2021.05.001 · Cited by 36
Imaging and treatment of brain tumors through molecular targeting: Recent clinical advances
Zaccagna, F., Grist, J. T., Quartuccio, N., Riemer, F., Fraioli, F., Caracò, C., Halsey, R., Aldalilah, Y., Cunningham, C. H., Massoud, T. F., et al. (2021) · European Journal of Radiology · doi:10.1016/j.ejrad.2021.109842 · Cited by 38
“for use in neuroendocrine tumors [131] and hematological malignancies [132].”
BackgroundA New [68Ga]Ga-HBED-CC-Bisphosphonate as a Bone Imaging Agent
Zha, Z., Wu, Z., Choi, S., et al. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00103 · Cited by 31
Malo, M. E., Allen, K. J. H., Jiao, R., Frank, C., Rickles, D. J., & Dadachova, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228721 · Cited by 32
Galbiati, A., Bocci, M., Gervasoni, S. I., Prodi, E., Malloci, G., Neri, D., & Cazzamalli, S. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01295 · Cited by 30
Coll, R. P., Bright, S. J., Martinus, D. K. J., Georgiou, D. K., Sawakuchi, G. O., & Manning, H. C. (2023) · Molecular Imaging and Biology · doi:10.1007/s11307-023-01857-y · Cited by 35
Qin, Y., Imobersteg, S., Blanc, A., Frank, S., Schibli, R., Béhé, M. P., & Grzmil, M. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12111088 · Cited by 37
Kossatz, S., Beer, A. J., & Notni, J. (2021) · Cancers · doi:10.3390/cancers13235958 · Cited by 28
Synthetic Approaches to the New Drugs Approved During 2022
France, S. P., Lindsey, E. A., McInturff, E. L., Berritt, S., Carney, D. W., DeForest, J. C., Fink, S. J., Flick, A. C., Gibson, T., Gray, K. C., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02374 · Cited by 31
Cancer-Targeting Applications of Cell-Penetrating Peptides
Moreno‐Vargas, L. M., & Prada‐Gracia, D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms26010002 · Cited by 31
FDA‐approved drugs featuring macrocycles or medium‐sized rings
Du, Y., Semghouli, A., Wang, Q., Mei, H., Kiss, L., Baecker, D., Soloshonok, V. A., & Han, J. (2025) · Archiv der Pharmazie · doi:10.1002/ardp.202400890 · Cited by 36
Bio-vehicles of cytotoxic drugs for delivery to tumor specific targets for cancer precision therapy
Al-Mansoori, L., Elsinga, P. H., & Goda, S. K. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112260 · Cited by 31
Optimizing the Safety and Efficacy of Bio-Radiopharmaceuticals for Cancer Therapy
Funeh, C. N., Bridoux, J., Ertveldt, T., Groof, T. W. M. D., Chigoho, D. M., Asiabi, P., Covens, P., D’Huyvetter, M., & Devoogdt, N. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15051378 · Cited by 30
Immunological effects of radiopharmaceutical therapy
Shea, A. G., Idrissou, M. B., Torres, A. I., Chen, T., Hernandez, R., Morris, Z. S., & Sodji, Q. H. (2024) · Frontiers in Nuclear Medicine · doi:10.3389/fnume.2024.1331364 · Cited by 28
212Pb in targeted radionuclide therapy: a review
Scaffidi-Muta, J. M., & Abell, A. D. (2025) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-025-00362-7 · Cited by 40
“The current standard of care for SSRT2 positive neuroendocrine tumours includes the β − emitter [ 177 Lu]Lu-DOTATATE, which contains the SSRT2 targeting peptide octreotide (Dierickx et al. 2020; Hennrich and Kopka 2019).”
Expanding the Scope of Pyclen-Picolinate Lanthanide Chelates to Potential Theranostic Applications
Nizou, G., Favaretto, C., Borgna, F., Grundler, P. V., Saffon‐Merceron, N., Platas‐Iglesias, C., Fougère, O., Rousseaux, O., van der Meulen, N. P., Müller, C., et al. (2020) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.0c01664 · Cited by 29
Si, Y., Guan, J.-S., Xu, Y., Chen, K., Kim, S., Zhou, L., Jaskula‐Sztul, R., & Liu, M. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12111079 · Cited by 26
Development of Heterobivalent Theranostic Probes Having High Affinity/Selectivity for the GRPR/PSMA
Bandari, R. P., Carmack, T. L., Malhotra, A., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01785 · Cited by 26
Silva, F., D’Onofrio, A., Mendes, C., Pinto, C. I. G., Marques, A., Campello, M. P. C., Oliveira, M. C., Raposinho, P., Belchior, A., Maria, S. D., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020617 · Cited by 30
Advances in macrocyclic chelators for positron emission tomography imaging
Li, M., Wang, S., Kong, Q., Cheng, X., Yan, H., Xing, Y., Lan, X., & Jiang, D. (2023) · View · doi:10.1002/viw.20230042 · Cited by 28
Radioligand Therapy in Cancer Management: A Global Perspective
Ninatti, G., Lee, S. T., & Scott, A. M. (2025) · Cancers · doi:10.3390/cancers17213412 · Cited by 36
Wharton, L., Yang, H., Jaraquemada-Peláez, M. D. G., Merkens, H., Engudar, G., Ingham, A., Koniar, H., Radchenko, V., Kunz, P., Schaffer, P. C., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01151 · Cited by 26
Towards Effective Targeted Alpha Therapy for Neuroendocrine Tumours: A Review
Gape, P. M. D., Schultz, M. K., Stasiuk, G. J., & Terry, S. Y. A. (2024) · Pharmaceuticals · doi:10.3390/ph17030334 · Cited by 29
“This positive result led to the approval of [ 177 Lu]Lu-DOTATATE, under the name Lutathera, in Europe by the European Medicines Agency in late 2017 and in America by the Food and Drug Administration in early 2018 [22].”
Shapiro, M. A. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1379738 · Cited by 24
Damiana, T. S. T., & Dalm, S. U. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050674 · Cited by 26
Patra, S., Chakravarty, R., Singh, K., Vimalnath, K. V., & Chakraborty, S. (2023) · Chemical Engineering Journal Advances · doi:10.1016/j.ceja.2023.100444 · Cited by 22
Sagar, B., Gupta, S., Verma, S. K., Reddy, Y. V. M., & Shukla, S. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.117131 · Cited by 25
Zhao, R., Plöessl, K., Zha, Z., et al. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00777 · Cited by 22
A High Separation Factor for 165Er from Ho for Targeted Radionuclide Therapy
Silva, I. D., Johnson, T. R., Mixdorf, J. C., Aluicio‐Sarduy, E., Barnhart, T. E., Nickles, R. J., Engle, J. W., & Ellison, P. A. (2021) · Molecules · doi:10.3390/molecules26247513 · Cited by 23
Kim, Y. (2020) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000001350 · Cited by 23
Metadata
- Authors
- Hennrich, U., & Kopka, K.
- Affiliations
- German Cancer Research Center (DE)
- Corresponding author
- Hennrich, Ute
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2019-07-29
- Volume
- 12
- Issue
- 3
- Pages
- 114
- ISSN
- 1424-8247 (ISSN-L)
- PMC
- PMC6789871
- OpenAlex
- W2965362447
- Semantic Scholar
- 541d92ea7d4ff1ddec5cefec2755259d1aa26d0e
- Cited by
- 440
- References
- 26
- Citations by year
- 2026: 58 · 2025: 87 · 2024: 88 · 2023: 61 · 2022: 58 · 2021: 46 · 2020: 38 · 2019: 3
- FWCI
- 5.29
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Pharmaceuticals (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- 177Lu-DOTATATE, lutetium-177, peptide receptor radionuclide therapy, somatostatin receptors, DOTATATE, gastroenteropancreatic neuroendocrine tumors, radiopharmaceuticals, targeted radionuclide therapy, DNA double-strand breaks, cancer cell death
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
![Figure 1 Structure of [177Lu]Lu-DOTA-TATE (Lutathera®). Simplified writing of complexation [18].](https://figures.cochat.ai/paper-figures/b252f6f0df3d4eceb221f630640ad0bc/lutathera-the-first-fda-and-ema-approved-radiopharmaceutical-for-peptide-figure-1.jpg)
![Figure 2 Simplified overview on the mechanism of action of [177Lu]Lu-DOTA-TATE.](https://figures.cochat.ai/paper-figures/56d8de000b344458a3f6939340017c5b/lutathera-the-first-fda-and-ema-approved-radiopharmaceutical-for-peptide-figure-2.jpg)